LncRNA PVT1 Regulates TRPS1 Expression in Breast Cancer by Sponging MiR-543
Overview
Authors
Affiliations
Background: Breast cancer is the most common female malignancy with high invasion and metastasis abilities. Studies have shown that long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 gene (PVT1) is an oncogene and is positively correlated with progression and metastasis of breast tumors. However, the detailed mechanism of PVT1 in breast cancer tumorigenesis is not fully understood.
Methods: Real-time polymerase quantitative chain reaction (RT-qPCR) was performed to identify the expression levels of PVT1, miR-543 and trichorhinophalangeal syndrome-1 gene (TRPS1) in breast cancer tissues and cells. Cell proliferation was measured by plate clone formation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide (MTT) assay. Apoptosis and motility of MCF-7 and MDA-MB-436 cells were assessed with flow cytometry assay and transwell migration and invasion analyses, respectively. In addition, a model was established to probe the function of PVT1 silencing in vivo. The target relationship among PVT1, miR-543 or TRPS1 was confirmed by dual-luciferase reporter analysis, RNA immunoprecipitation (RIP) and RNA pull down assays. The protein expression level of TRPS1 was evaluated with Western blot assay.
Results: PVT1 expression was upregulated in breast cancer tissues and cell lines. In addition, PVT1 silencing inhibited breast cancer cell growth and motility, while increased apoptosis. Meanwhile, the effects of PVT1 or miR-543 could be reversed by introducing overexpressed plasmid of miR-543 or TRPS1 in breast cancer cell lines, respectively.
Conclusion: Knockdown of PVT1 repressed breast cancer cell growth and motility, and induced apoptosis in vitro and reduced tumor volume and weight in vivo. Mechanically, the overexpression of PVT1 enhanced TRPS1 level by negatively targeted miR-543 in breast cancer.
LncRNAs has been identified as regulators of Myeloid-derived suppressor cells in lung cancer.
Liu Y, Han Y, Zhang Y, Lv T, Peng X, Huang J Front Immunol. 2023; 14:1067520.
PMID: 36817434 PMC: 9932034. DOI: 10.3389/fimmu.2023.1067520.
MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK31 axis.
Liu Y, Wei J, Wang C, Meng Z, Luo D, Zhao X J Gastrointest Oncol. 2023; 13(6):3263-3277.
PMID: 36636045 PMC: 9830362. DOI: 10.21037/jgo-22-1017.
Noncoding RNA PVT1 in osteosarcoma: The roles of lncRNA PVT1 and circPVT1.
Wu T, Ji Z, Lin H, Wei B, Xie G, Ji G Cell Death Discov. 2022; 8(1):456.
PMID: 36379920 PMC: 9666356. DOI: 10.1038/s41420-022-01192-1.
lncRNA PVT1: a novel oncogene in multiple cancers.
Li R, Wang X, Zhu C, Wang K Cell Mol Biol Lett. 2022; 27(1):84.
PMID: 36195846 PMC: 9533616. DOI: 10.1186/s11658-022-00385-x.
Long non-coding RNA PVT1: A promising chemotherapy and radiotherapy sensitizer.
Yao W, Li S, Liu R, Jiang M, Gao L, Lu Y Front Oncol. 2022; 12:959208.
PMID: 35965522 PMC: 9373174. DOI: 10.3389/fonc.2022.959208.